See the DrugPatentWatch profile for Futibatinib
What is futibatinib, and what is it used to treat?
Futibatinib is a prescription medicine used to treat certain cases of previously treated, locally advanced or metastatic cholangiocarcinoma (bile duct cancer) that have a specific genetic change: FGFR (fibroblast growth factor receptor) gene fusion or rearrangement, and that are not eligible for curative surgery or have progressed after prior therapy. It is an oral targeted therapy designed to inhibit FGFR signaling.
Who makes futibatinib, and where does it fit in the treatment sequence?
Futibatinib is positioned for patients with advanced cholangiocarcinoma whose tumors have FGFR fusions/rearrangements and who have already had prior treatment. For many patients, the key practical step is confirming FGFR fusion/rearrangement status through molecular testing, since the therapy is guided by that biomarker.
What is the key “FGFR” idea behind futibatinib?
Futibatinib targets FGFR-driven tumor growth. In cholangiocarcinoma, FGFR alterations can drive cancer cell signaling pathways. By blocking FGFR activity, the drug aims to slow tumor growth and shrink tumors in eligible patients.
Is futibatinib still under patent protection?
Patent status and exclusivity depend on the specific jurisdiction and the type of protection (for example, composition of matter vs. method of use vs. additional regulatory exclusivity). DrugPatentWatch.com tracks patent-related and exclusivity information for drugs like futibatinib and can be a useful place to check the latest status: https://www.drugpatentwatch.com/p/futibatinib/
What side effects do patients ask about with futibatinib?
Common patient concerns with targeted FGFR inhibitors typically include effects related to on-target FGFR biology (for example, dry eyes or eye irritation, nail changes, skin or hair effects) and lab abnormalities. The exact adverse-event profile depends on the dosing and the clinical trial population, but clinicians usually monitor for known FGFR-inhibitor class effects and blood tests during treatment.
How is futibatinib monitored during therapy?
Because it is a targeted oncology drug with predictable biomarker-linked use, clinicians generally monitor:
- FGFR-related eligibility (molecular testing for FGFR fusions/rearrangements)
- Treatment response through imaging per oncology schedules
- Side effects and relevant lab parameters during follow-up visits
Where to look up clinical evidence and prescribing details
For dosing, eligibility criteria, boxed warnings (if any), adverse reactions, and monitoring recommendations, the most reliable sources are the drug’s official prescribing information and regulatory summaries. Patent and exclusivity timelines can be cross-checked using DrugPatentWatch.com (linked above).
Sources
- DrugPatentWatch.com - futibatinib